2born (2born) wrote,
2born
2born

Терапия опухолей ионами гелия

Helium beam particle therapy facility
Mariusz Sapinski
Due to its precision and limited side effects, the particle therapy of cancer is gaining popularity. The number of patients treated with protons and light ions reached 150,000 worldwide. There are currently more than 80 facilities, which often this treatment and several dozen of new ones are in construction. Mostly they are cyclotron-based facilities, which provide proton beams, and only several are synchrotron-based facilities that provide both: proton and carbon-ion beams. The advantage of carbon ions is their higher efficiency in destroying the cancer cells, more localized shape of the Bragg peak and smaller beam scattering in the body. Several of the large centers, which can provide carbon, have experimented with other ions including helium. The advantage of helium over protons is significantly larger precision of the treatment due to lower scattering of alpha particles in the body, especially important for pediatric patients. A facility with therapeutic beams limited to helium, would be smaller and cheaper than carbon-based facility. Here we discuss this option.
Tags: медицинская физика, разгребая arXiv'ы, техника
Subscribe

  • Новость часа: монография вышла из печати!

    Ссылка на сайте издательства (содержание и возможность заказа). Содержание: Введение Глава 1. Динамика быстрых заряженных частиц в кристалле…

  • Об уравнениях Вольтерра

    Не по моей части, но вдруг кому-то пригодится. Завлекают разобранными примерами:)) A Spectral Theory of Scalar Volterra Equations…

  • Need help!

    Кто-нибудь из уважаемых читателей имел дело с гистограммами в логарифмическом масштабе? Это когда бины одинаковые по ширине на логарифмической оси…

  • Post a new comment

    Error

    default userpic

    Your reply will be screened

    Your IP address will be recorded 

    When you submit the form an invisible reCAPTCHA check will be performed.
    You must follow the Privacy Policy and Google Terms of use.
  • 0 comments